Status:
COMPLETED
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
Phase:
PHASE4
Brief Summary
The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen ...
Eligibility Criteria
Inclusion
- Postmenopausal patients
- Patients with early breast cancer after adequate loco-regional treatment and eventual adjuvant chemotherapy, treated with tamoxifen for 2-3 years OR treated with tamoxifen for 2-3 years and consecutive exemestane treatment, provided the total duration of endocrine treatment is less than 5 years
- Estrogen receptor positive breast cancer patients
- Patients who remain free from disease following treatment with tamoxifen
Exclusion
- Patients taking other drugs for the adjuvant treatment of breast cancer
- Patients taking hormone replacement therapy
- Donation of blood or blood products for transfusion during the 30 days prior to initiation of treatment with study drug, at any time during the program or 30 days after completion of treatment
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
1549 Patients enrolled
Trial Details
Trial ID
NCT00649090
Start Date
March 1 2005
End Date
April 1 2007
Last Update
September 29 2008
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aalst, Belgium, 9300
2
Pfizer Investigational Site
Antwerp, Belgium, 2020
3
Pfizer Investigational Site
Arlon, Belgium, 6700
4
Pfizer Investigational Site
Baudour, Belgium, 7331